ストックスクリーナーアプリを入手
3.91
8.64%
-0.37
プレマーケット:
3.95
0.04
+1.02%
前日終値:
$4.28
開ける：
$4.3
24時間の取引高:
2.07M
Relative Volume:
1.78
時価総額：
$260.12M
収益：
$488.00K
当期純損益:
$-41.44M
株価収益率:
-4.2043
EPS:
-0.93
ネットキャッシュフロー:
$-31.47M
1週間 パフォーマンス:
-5.33%
1か月 パフォーマンス:
+26.13%
6か月 パフォーマンス:
+11.08%
1年 パフォーマンス:
+73.78%
1日の値動き範囲:
$3.87
$4.35
1週間の範囲:
$3.87
$4.555
52週間の値動き範囲:
$2.01
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
名前
Cardiff Oncology Inc
セクター
電話
858-952-7570
住所
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
3.91 | 274.75M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2025-06-24 | 開始されました | Jefferies | Hold |
| 2024-09-06 | 開始されました | Craig Hallum | Buy |
| 2022-01-05 | 開始されました | William Blair | Outperform |
| 2021-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-09 | 再開されました | Maxim Group | Buy |
| 2020-10-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Cardiff Oncology Inc (CRDF) 最新ニュース
Cardiff Oncology Inc. Stock Analysis and ForecastOutstanding capital growth - jammulinksnews.com
What drives Cardiff Oncology Inc. stock priceOverwhelming financial success - jammulinksnews.com
What analysts say about Cardiff Oncology Inc. stockBreakout portfolio performance - jammulinksnews.com
Is Cardiff Oncology Inc. a good long term investmentMassive portfolio appreciation - PrintWeekIndia
Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term (NASDAQ:CRDF) - Seeking Alpha
How Cardiff Oncology Inc. stock performs during market volatilityHigh Return Setup Scanner - Newser
What makes Cardiff Oncology Inc. stock price move sharplyInvestor Favorite Picks - Newser
Why Cardiff Oncology Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
Cardiff Oncology (CRDF) Initiated with a Buy at Ladenburg Thalmann & Co. - The Globe and Mail
Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH - Defense World
Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $11.70 - Defense World
Cardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + Paclitaxel - MSN
Cardiff Oncology stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com Canada
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - GlobeNewswire
International Business Times - FinancialContent
Cardiff Oncology Up 16%, Insider Buyers Are Up 35% - simplywall.st
While institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the most - Yahoo Finance
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
Rhumbline Advisers Grows Stock Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Jefferies Initiates Coverage on Cardiff Oncology (CRDF) with Hol - GuruFocus
Cardiff Oncology (CRDF) Begins Coverage With Hold Rating from Jefferies | CRDF Stock News - GuruFocus
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga
Cardiff Oncology stock initiated at Hold by Jefferies on early data concerns - Investing.com
Market Overreaction to Cardiff Oncology's Data Delay Presents a Rare Buying Opportunity - AInvest
Cardiff Oncology (CRDF) Stock Reacts to Delayed Clinical Data Up - GuruFocus
Cardiff Oncology falls after naming new medical chief ahead of key trial readout - MSN
CRDF Set to Release Key Clinical Data Amid Leadership Changes | CRDF Stock News - GuruFocus
Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer By Investing.com - Investing.com India
Cardiff Oncology (CRDF) Welcomes New Chief Medical Officer | CRD - GuruFocus
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Offic - GuruFocus
Cardiff Oncology (CRDF) Shares Drop 11% After Leadership Change - GuruFocus
Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer - MarketScreener
Cardiff Oncology stock falls as new medical chief named (CRDF) - Seeking Alpha
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical - GlobeNewswire
Cardiff Oncology Names New Chief Medical Officer - marketscreener.com
Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer - Investing.com
Bank of America Corp DE Sells 11,352 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology's Leadership Shift and Clinical Catalysts: A New Chapter for Onvansertib? - AInvest
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
Two Sigma Investments LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Two Sigma Advisers LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
ProShare Advisors LLC Acquires New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Nuveen Asset Management LLC Acquires 248,850 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Deutsche Bank AG Acquires Shares of 49,566 Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Millennium Management LLC Buys 288,259 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology reports positive trial results for breast cancer treatment By Investing.com - Investing.com India
Cardiff Oncology (CRDF) Reports Promising Phase 1b Trial Results for Breast Cancer Treatment | CRDF Stock News - GuruFocus
Cardiff Oncology Inc (CRDF) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.17%
大文字化:
|
ボリューム (24 時間):